GU Cast | Urology Podcast

So said UCSF Oncologist and major league podcaster Dr Vinay Prasad in his recent Plenary Session podcast, reviewing the VISION trial in NEJM. We have already covered VISION here at GU Cast, but we decided to invite Vinay on the podcast to de-visit VISION and other aspects of trial design. Vinay is a Haematologist Oncologist at the University of California, San Francisco, and researcher interested...

This one really slipped under the radar when the National Comprehensive Cancer Centre Network (NCCN) Prostate Cancer Guideline Panel released their updated guidelines a few weeks ago. That is until Dr Dan Lin mentioned it to Dr Matt Cooperberg, who promptly flagged it to his very large Twitter following. And what a reaction! Almost universally panned by the urological community, especially advocat...

Some huge data coming out of #ESMO21 this week! And as ever, the amazing STAMPEDE trial delivers another practice-changing headline grabber. This time it's a focus on so-called "M0 high-risk" patients in STAMPEDE, with clear data showing that the addition of two years of abiratrone acetate to standard of care provides a massive benefit in metastasis-free survival and overall surviva...

Are GU Cast overly interested in PSMA imaging and theranostics??! Yep, afraid so! So no surprise that we're featuring this very interesting prospective trial published in European Urology this week. The objective is to evaluate the role of PSMA PET/CT prior to prostate biopsy ie in the early detection space. Can this augment mpMRI? Or replace it? Or is it all just madness due to profligate ac...

So there we were, thinking we did a nice job highlighting the #Manels paper published in European Urology recently, and basking a little bit in the glow of positivity it brought to the topic of gender diversity in Urology. We were also really pleased to see the accompanying Editorial which outlined the European Urology position on gender diversity and equality, led by Associate Editor Professor Sa...

This headline may be true (check our YouTube version for proof!), but the bromance certainly hit a bumpy patch when it came to discussing Keynote 564 on GU Cast today! We congratulate Dr Toni Chouieri (Medical Oncologist and Director of the Lank Center for GU Oncology, Dana Farber Cancer Institute), and colleagues for the publication of Keynote 564 in NEJM recently, and to Toni for his plenary at...

These two old mates join us for a "robust discussion" on the role of prostate MRI in the early detection of prostate cancer! Dr Ben Davies, Professor of Urology, University of Pittsburgh, and Dr Matt Cooperberg, Urologic Oncologist at the University of California,  San Francisco,  certainly have differing views on the value of MRI in the early detection of prostate cancer. This was most...

In May 2018, Urologist Dr Daron Smith of University College Hospital, London, wrote an impassioned open letter to announce that he was stepping down as an educational supervisor in urology, due to his frustration with the burdensome administrative tools embedded in the UK surgical training system. His message resonated with many. This month, a new curriculum and training system comes into effect,...

Transperineal biopsy has gone from being a fringe pursuit for a bunch of enthusiasts, into primetime in countries like Australia and the UK where it accounts for more than 50% of prostate biopsies. We are joined today by Associate Professor Jeremy Grummet, Urologist at Alfred Health and Monash Medical School, who has been a long-standing proponent of transperineal prostate biopsy, and who contribu...

GU Cast once again joins up with our friends at the Prostate Cancer Foundation (PCF), and the Prostate Cancer Imaging & Theranostics Centre of Excellence (ProsTIC) at Peter MacCallum Cancer Centre to bring you another Global Webinar focussing on PSMA theranostics. Today's webinar features the VISION trial, recently published in the New England Journal of Medicine, and includes the first a...

Tim O'Brien returns to GU Cast today, basking in the afterglow of a very successful British Association of Urological Surgeons (BAUS) Annual Meeting, virtual of course. Tim last joined us in August 2020 when he had just taken up the reins as BAUS President, and was dealing with the challenge of running a virtual BAUS Annual Meeting. One year on, and following a very well received virtual BAUS...

Fascinating GU Cast today focussing on the role of MRI scanning for patients on active surveillance (AS) for prostate cancer. We are joined by two of the world's leading experts on prostate MRI to discuss two recent systematic reviews on this topic.  Professor Anwar Padhani, Radiologist at Mt Vernon Cancer Centre and the Institute of Cancer Research  in London, and Professor Caroline Moore, U...

Cracking episode today, following hot on the heels of the systematic review recently published in European Urology focussing on #manels in urology. We cross the globe to hear from first author Dr Jeremy Teoh in Hong Kong, senior author Dr Maria Ribal in Barcelona, and co-authors Dr Stacy Loeb in New York, and our own Declan Murphy in Melbourne. This paper has got a big reaction on social media and...

Big week for prostate cancer ( especially for PSMA enthusiasts like us!), with the phase III VISION trial heading the plenary session at the ASCO Annual Meeting. VISION is the long-awaited pivotal randomised trial of Lu-PSMA vs standard of care for men with progressive mCRPC following chemo +/- AR pathway inhibitors. Lots of stuff to dive into, even as we await the NEJM paper. We scrutinise the co...

Today Declan and Renu recall one of the highlights of ASCO GU 2020 (the last real physical meeting!!),  when Dr David Penson delivered his keynote address on financial toxicity in GU Oncology. David's team also followed up with a fantastic systematic review on this completely under-discussed topic in European Urology Oncology recently (link below). David is Professor and Chair of Urology at V...

GU Cast is back! Declan and Renu took a break over the Melbourne Summer and are fully recharged with a great schedule of podcasts coming up for 2021. We kick off today with the fourth in our series of webinar collaborations with the Prostate Cancer Foundation and the ProsTIC team at Peter MacCallum Cancer Centre. Today's webinar had 589 live attendees from more than 40 countries, tuning in to...

Today we are getting together on New Year's Eve 2020 to look back on the year that was. Very forgettable for many reasons(!), but also some great moments on GU Cast that we want to share with you on our Year in Review podcast.  Since our launch episode in March 2020, we have posted 45 episodes and have had many thousands of downloads every month. Our audience  is truly global with listeners f...

We know that many of our listeners are in the depths of a tough COVID Winter in the Northern Hemisphere, so we thought we might bring you some summer cheer from Australia where the sun is shining and COVID is less of an issue!  We have joined with our friends at PROSPECT, a prostate cancer educational initiative which has been running in Australia for eight years. to bring you a 3-part podcast sum...

Big day today with the approval of Ga68-PSMA PET/CT by the US Food and Drugs Administration (FDA). The FDA have approved a combined academic application from the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA), and means that those two centres now have FDA approval to use PSMA PET/CT for staging newly-diagnosed prostate cancer, as well as those wit...

"Men urged to harden up on prostate health " - so goes the title of Libbi Gorr's interview with our own Declan Murphy when she chatted with him this week on her ABC Radio show, "This Weekend Life". A no-holds barred chat on all things prostate to coincide with Movember. Featuring calls from patients, and a discussion about how often men should ejaculate! Links Libbi's...

The European Association of Nuclear Medicine (EANM) Annual Meeting is the world's leading nuclear medicine congress, and took place (virtually) last week. From being a very minor part of nuclear medicine just a few years ago, GU Oncology is now one of the most exciting areas in nuclear medicine, and this year's EANM Meeting featured a huge amount of original research in prostate cancer a...

It's that time of year again, and we are celebrating all things Mo with Paul Villanti, Executive Director at Movember. From its humble origins here in Melbourne 13 years ago, the Movember campaign has raised more than AUD$1.1bn over the past 13 years, funding more than 1250 projects around the world aimed at improving men's health. Quiet amazing, and a lot of fun. Prostate and testicular...

Today we focus on the NAVIGATE study,  a randomised trial of an online decision aid for men and their partners recently diagnosed with localised prostate cancer. Active surveillance is the preferred option for many men with low-risk prostate cancer, and may also be recommended for some men with favourable intermediate-risk prostate cancer, but many patients find the idea of surveillance to be stre...

Regular GU Cast guest, Dr Ben Tran, joins us today to review some highlights from the recent virtual #ESMO20 Annual Meeting. Ben made headlines himself at this year's meeting as he presented his phase 1 study of AMG160 was selected for the prostate cancer plenary session (you got to tune in to hear him explain what a half-life extended bi-specific T cell engager is! Peter Mac Phase I and GU F...

Exciting day today with the publication of the first edition of a brand new urology journal! And not one of those horrible predatory journals that we all get harassed by. The Societe Internationale d'Urologie (SIU) is one of the leading organisations in urology and has a long history of partnering with other major journals to output their scientific content. It has now decided to publish its...